TELMIGEN Telmisartan 40mg Tablet 1's
TELMISA-OXRTES
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
TELMIGEN
Full Details
Dosage Strength
40mg
Drug Ingredients
- Telmisartan
Drug Packaging
Tablet 1's
Generic Name
Telmisartan
Dosage Form
Tablet
Registration Number
DRP-11041
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Hypertension: Treatment of essential hypertension in adults.
Cardiovascular prevention: Reduction of cardiovascular morbidity in adults with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.
Cardiovascular prevention: Reduction of cardiovascular morbidity in adults with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.
Dosage/Direction for Use
Hypertension: Usual starting dose: 40 mg once a day.
Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks.
When additional blood pressure reduction beyond that achieved with 80 mg telmisartan is required, a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
Cardiovascular risk reduction: Recommended dose: 80 mg once a day.
It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality.
When initiating telmisartan therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
Telmisartan tablets may be administered with other antihypertensive agents. Telmisartan tablets may be administered with or without food.
Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks.
When additional blood pressure reduction beyond that achieved with 80 mg telmisartan is required, a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
Cardiovascular risk reduction: Recommended dose: 80 mg once a day.
It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality.
When initiating telmisartan therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
Telmisartan tablets may be administered with other antihypertensive agents. Telmisartan tablets may be administered with or without food.
Administration
May be taken with or without food.
Contraindications
Second and third trimesters of pregnancy.
Biliary obstructive disorders.
Severe hepatic impairment.
Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73m2).
Biliary obstructive disorders.
Severe hepatic impairment.
Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73m2).
Special Precautions
Dual blockade of RAAS through combination w/ ACE inhibitors or aliskiren is not recommended. Not to be used concomitantly w/ ACE inhibitors in patients w/ diabetic nephropathy. Not recommended in patients w/ primary aldosteronism. Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Hyperkalemia. Patients w/ aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy; severe CHF or underlying renal disease including renal artery stenosis; ischemic cardiopathy or CV disease. Correct symptomatic hypotension prior to administration in patients who are vol &/or Na depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting. Periodically monitor K & creatinine serum levels in patients w/ renal impairment. Not recommended during pregnancy (1st trimester) & lactation.
Storage
Store at temperatures not exceeding 30°C.
MedsGo Class
Angiotensin II Antagonists
Please sign in so that we can notify you about a reply